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Genetic variants in the genomic region containing SORT1 (encoding the protein sortilin)
are strongly associated with cholesterol levels and the risk of coronary artery disease
(CAD). Circulating sortilin has therefore been proposed as a potential biomarker for
cardiovascular disease. Multiple studies have reported association between plasma
sortilin levels and cardiovascular outcomes. However, the findings are not consistent
across studies, and most studies have small sample sizes. The aim of this study
was to evaluate sortilin as a biomarker for CAD in a well-characterized cohort with
symptoms suggestive of CAD. In total, we enrolled 1,173 patients with suspected
stable CAD referred to coronary computed tomography angiography. Sortilin was
measured in plasma using two different technologies for quantifying circulating sortilin: a
custom-made enzyme-linked immunosorbent assay (ELISA) and OLINK Cardiovascular
Panel II. We found a relative poor correlation between the two methods (correlation
coefficient = 0.21). In addition, genotyping and whole-genome sequencing were
performed on all patients. By whole-genome regression analysis of sortilin levels
measured with ELISA and OLINK, two independent cis protein quantitative trait loci
(pQTL) on chromosome 1p13.3 were identified, with one of them being a well-established
risk locus for CAD. Incorporating rare genetic variants from whole-genome sequence
data did not identify any additional pQTLs for plasma sortilin. None of the traditional CAD
risk factors, such as sex, age, smoking, and statin use, were associated with plasma
sortilin levels. Furthermore, there was no association between circulating sortilin levels
and coronary artery calcium score (CACS) or disease severity. Sortilin did not improve
discrimination of obstructive CAD, when added to a clinical pretest probability (PTP)
model for CAD. Overall, our results indicate that studies using different methodologies
for measuring circulating sortilin should be compared with caution. In conclusion, the
well-known SORT1 risk locus for CAD is linked to lower sortilin levels in circulation,
measured with ELISA; however, the effect sizes are too small for sortilin to be a useful
biomarker for CAD in a clinical setting of low- to intermediate-risk chest-pain patients.
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INTRODUCTION
Coronary artery disease (CAD) is a common complex disease
with a strong genetic contribution. A large number of genome-
wide association studies (GWASs) have been conducted to
identify risk loci and genes involved in the development
of early onset myocardial infarction (1, 2), various aspects
of atherosclerosis (3–6), and low-density lipoprotein (LDL)
cholesterol levels (7–10). Since 2007, several new candidate
genes affecting LDL cholesterol have been identified by GWAS,
including the SORT1 locus (7).
The SORT1 locus on chromosome 1p13.3 is broad and
comprises the genes CELSR2-PSRC1-MYBPHL-SORT1. The
majority of LDL cholesterol–associated single-nucleotide
polymorphisms (SNPs) are located in the intergenic region
between PSRC1 and CELSR2, and downstream of SORT1
and MYBPHL (11). In addition, SNPs in the same genomic
region have been found to convey changes in transcript
levels of SORT1, CELSR2, and PSRC1 (12). Fine-mapping
studies have found that genetic variants in the major (risk)
haplotype block containing rs599834, rs646776, rs629301, and
rs12740374 are associated with lower SORT1, CELSR2, and
PSRC1 transcript levels in the human liver (12, 13). Thus, it is
difficult to exactly pinpoint which gene(s) is(are) responsible
for the risk of developing CAD, although it is believed that the
CAD risk variant at 1p13.3 alters the levels of sortilin in the
liver (12).
Apart from being strongly associated with plasma LDL
cholesterol levels, the SORT1 locus is also associated with CAD
(3, 5, 6, 8, 14–17) and a wide range of different vascular
subphenotypes including early-onset myocardial infarction (1,
2), coronary stenosis (5, 8), coronary artery calcification (6),
abdominal aorta aneurysm (4), and aortic valve calcification
(18). These associations are likely an effect of increased LDL
cholesterol. Sortilin binds ApoB to facilitate hepatic export of
very low-density lipoprotein in mouse models (19). Sortilin also
augments PCSK9 secretion and increases the development of
atherosclerosis (12, 19–21). Animal and cell studies demonstrate
that sortilin also has a cholesterol-independent effect on
atherosclerosis, where sortilin is involved in inflammation and
calcification of the vessel wall (22, 23).
In addition to the liver, sortilin is also expressed in tissues that
are involved in atherosclerosis development, including smooth
muscle cells and macrophages (19, 22, 23). Notably, it is released
from smoothmuscle cells as a full-length receptor in extracellular
vesicles (23), but also liberated from thrombocytes in a soluble
form comprising the entire extracellular domain upon activation
and degranulation (24). The biological functions of the vesicular
and soluble receptor isoforms remain unknown.
Regardless of the source of varying levels of circulating
sortilin, it has been proposed as a potential biomarker for
cardiovascular diseases. Several studies have found association
between plasma sortilin and various cardiovascular phenotypes,
such as statin efficacy (25), PCSK9 levels (21, 25), CAD (24, 26),
major adverse cardiovascular event risk (27), aortic calcification
(27), and peripheral artery disease (28), but not with LDL
cholesterol (29).
In this study, we measured plasma sortilin using two different
methods in a cohort of low- to intermediate-risk patients
(n = 1,173) with symptoms suggestive of CAD. All patients
were referred to coronary computed tomography angiography
(CTA) and are thus well-characterized with respect to coronary
calcium score and clinical variables. Sortilin was measured using
OLINK Cardiovascular Panel II (CVD II) and a high-sensitivity
sortilin enzyme-linked immunosorbent assay (ELISA) developed
in-house. The aim of this study was to evaluate sortilin as
a biomarker for CAD in a well-characterized cohort by (1)
identifying genetic variants associated with variation in plasma
sortilin level, (2) analyzing the effect of common clinical risk
factors for CADon sortilin levels, (3) investigating the association
of sortilin with coronary calcium score and CAD severity, and (4)
testing if circulating sortilin could improve risk stratification of
patients with symptoms of CAD.
MATERIALS AND METHODS
Cohort Description
The study design of the Dan-NICAD 1 trial has been described
previously (30, 31). In short, Dan-NICAD 1 is a prospective,
multicenter, cross-sectional study including patients with low
to intermediate pretest probability (PTP) of CAD, no previous
history of CAD, and referred to coronary CTA because of
symptoms suggestive of CAD, as evaluated by a cardiologist.
Patients with signs of obstructive CAD by coronary CTA
were referred to invasive coronary angiography (ICA) with
fractional flow reserve (FFR) measurements to verify suspected
obstructions. Obstructive CAD was defined as an FFR of <0.80
or as high-grade stenosis (>90% diameter stenosis) by visual
assessment. Major exclusion criteria were age younger than 40
years and eGFR <40 mL/min.
Blood samples from all participants were drawn in connection
with the coronary CTA. EDTA and heparin plasma were isolated
and stored at −80◦C. Of the full Dan-NICAD 1 trial comprising
1,675 patients, heparin plasma was available for 1,173 patients
for ELISA. The OLINK CVD II panel was analyzed on the full
cohort. To ensure head-to-head comparison of the two sortilin
datasets, we included only the 1,173 consecutive patients, which
had sortilin information from both methods. The study protocol
was approved by the regional research ethical committee, and
written consent was obtained.
Coronary CTA and Invasive Angiography
All scans were performed on a 320-slice volume CT scanner
(Aquilion One; Toshiba Medical Systems, Japan) in accordance
with usual clinical guidelines. Imaging analysis included an
Agatston coronary artery calcium score (CACS) and visual
evaluation of luminal diameter stenosis estimation in each
coronary segment. CAD severity at CTA was classified by
diameter stenosis reduction in all segments with a reference
vessel diameter >2mm as no CAD: 0%; mild CAD: 1 to <30%;
moderate CAD: >30 to <50%; and severe CAD: ≥50% diameter
stenosis reduction.
Approximately 4 weeks after the coronary CTA, ICA was
performed in patients with a suspected severe CAD at coronary
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CTA. ICA with FFR was performed in all segments with
a 30–90% diameter stenosis at the ICA. Two-dimensional
quantitative coronary analysis (QCA) was performed in an
independent core laboratory (ClinFact, Leiden, the Netherlands).
Hemodynamically obstructive CAD was defined as high-grade
stenosis by visual assessment (>90% diameter stenosis) or by an
ICA-FFR ≤0.80 in a vessel of ≥2.0-mm diameter. If ICA-FFR
was indicated but not technically possible, QCA-based stenosis
assessment was used with a cutoff of ≥50% diameter reduction.
All other patients, including patients without severe CAD at
coronary CTA, were classified as having no hemodynamically
obstructive CAD.
Protein Measurements
Levels of circulating sortilin were quantified using the OLINK
platform and a high-sensitivity ELISA assay developed in-house.
Plasma was collected at two different geographical locations
(collection sites) in Denmark over a period of 2 years (30).
OLINK
EDTA plasma samples in 96-well matrix tubes were shipped to
OLINK proteomics AB (Uppsala, Sweden) on dry ice for analysis
using the proximity extension assay (PEA) technology. Levels
of 92 proteins from the CVD II panel were measured, among
them sortilin. Samples were replated and randomly distributed
across assay plates at the OLINK analysis facility to allow
for control of technical batch effects. The final assay read-out
was Normalized Protein eXpression (NPX) values, which is an
arbitrary unit on a log2 scale where high values correspond to
higher protein levels. Using an internal extension control and an
interpolate control, data quality was controlled and normalized.
All assay validation data are available on the manufacturer’s
website (www.olink.com).
High-Sensitivity Custom-Made ELISA
Heparin plasma was thawed and measured using a custom-made
ELISA against human soluble sortilin. In short, 96-well plate
Nunc Maxisorp was coated with anti–human soluble sortilin
[custom made against EC domain as described by Petersen
et al. (32)] 1 µg per well in 55mM NaHCO3 pH 9.8. The
wells were subsequently blocked with 5% bovine serum albumin
(BSA) (Sigma A7888) in phosphate-buffered saline (PBS) (pH
7.4). Washing was done in PBS-T (pH 7.4). Sample, internal
control, and standard were incubated overnight at 4◦C. Standard
curve was made from 0.625 to 160 ng/mL of purified human
soluble sortilin (21). The in-house generated detection antibody
(MABN1792, Sigma) was diluted in PBS-T with 1% BSA to
1µg/mL. One hundred microliters of the solution was added to
each well and allowed to incubate at 37◦C for 1 h. Finally, plates
were incubated with peroxidase-conjugated goat anti–mouse
immunoglobulin G (Dako) for 30min at room temperature
and rinsed five times before addition of o-phenylenediamine
dihydrochloride (Dako) mixed with hydrogen peroxide. The
reaction was stopped using 0.5M sulfuric acid, and absorbance
was subsequently measured at 490 nm.
To investigate if the anticoagulant used (heparin vs. EDTA)
affected the measurable sortilin level, a subset of 44 Dan-NICAD
individuals was randomly selected. In a paired design, sortilin was
measured again in both EDTA and heparin plasma samples using
the same approach as described above.
Normalization of Protein Levels
For EDTA plasma, variation linked to collection site
(Supplementary Figure 1A) and OLINK analysis plate
(Supplementary Figure 1B) was observed. For heparin plasma,
variation linked to analysis plate (custom-made ELISA) was
observed (Supplementary Figure 2). To account for the
observed batch effects, the raw data were adjusted using linear
regression. In this process, the sortilin measurements were
first normalized using rank inverse (to obtain normality) and
then adjusted for covariates [sex, age, age2, collection box ID,
average protein level for OLINK CVD panels II and III (only
for OLINK), and ELISA plate ID (only for ELISA)] using
linear regression, and finally the adjusted values were once
again normalized using rank inverse to address deviations from
normality (Supplementary Figure 3).
Genetic Data
Genotyping
Genomic DNA was isolated from frozen whole blood collected
in 4mL EDTA tubes. Genotyping was performed at deCODE
Genetics using the Illumina Global Screening Array (Illumina,
Inc., San Diego, CA). Quality control was performed in PLINK
1.9 (33) according to Marees et al. (34), accounting for individual
and SNP missingness (–geno 0.02, –mind 0.02), sex discrepancy
(–check-sex), minor allele frequency (–maf 0.05), and deviation
from Hardy–Weinberg equilibrium (–hwe 1 × 10−6), resulting
in 310,531 autosomal genetic variants. To account for cryptic
relatedness, first- and second-degree relatives were identified
based on identity by descent (π̂ > 0.2) computed by PLINK 1.9
(one sample was removed). Multidimensional scaling by PLINK
was applied to identify ancestral outliers (26 samples removed).
Imputation
Imputation was performed using the Michigan Imputation
Server (35) based on 310,531 genotyped variants (reference panel
HRC: r1.1.2016 GRCh37). SNPs with minor allele frequency
below 0.05, missing genotype rate larger than 5%, deviation from
Hardy–Weinberg equilibrium (P < 1 × 10−6), and imputation
quality below 0.9 were removed, resulting in a total of 4,658,994
autosomal genetic variants, with positions annotated to genome
build GRCh37.
Whole-Genome Sequencing
Whole-genome sequencing was performed using paired end
sequencing with an average depth of 30 on the Illumina NovaSeq
6000 sequencing platform at deCODE genetics. Reads were
processed in the quality control pipeline described by Jónsson
et al. (36). A total of 52,783,013 autosomal variants were detected
in the whole-genome sequencing data.
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Variance Explained by Common Genetic
Variants
The proportion of variation in circulating sortilin that can be
explained by common genetic variants, h2SNP, was estimated
with genomic restrict maximum likelihood as implemented in
the qgg package (37). First, the additive genomic relationship
matrix was constructed as G = (WW
′)
m , where W is the centered
and scaled genotype matrix, and m is the number of genotypes
(m = 4,658,994) (38). Next, variance components from the
linear mixed model were estimated: y = Xb + Zg + e, where
y is a vector of phenotypes (i.e., either sortilin level by OLINK
or ELISA), X and Z are design matrices linking the predicted
fixed effects (b̂) and the estimated random effects (ĝ) to the
phenotype, and e is the remaining unexplained residuals. The
included fixed effects were the same set of covariates as used
in the genetic association analysis. The estimate of h2SNP was







, where σ̂ 2g and σ̂
2
e are the estimated
variance components of the random effects; ĝ ∼ N(0,Gσ̂ 2g ), ê ∼
N(0, Iσ̂ 2e ), where I is an identity matrix (assuming uncorrelated
residuals) (37, 39).
Protein Quantitative Trait Loci Analysis
To investigate if specific loci in the genome were associated
with circulating sortilin levels, a protein quantitative trait loci
(pQTL) analysis was performed, testing the association of
4,658,994 autosomal genetic variants with circulating sortilin
levels using PLINK 2.0 (33). Prior to the analysis, genetic
principal components were computed in PLINK using a set of
high-quality autosomal genotyped variants (m = 310,531), to
investigate if there remained any population stratification in the
reduced set of individuals. Expectedly, as the Danish population
is remarkably homogeneous (40), and we have removed ancestral
outliers, we found no significant association between genetic
principal components and sortilin levels; therefore, these were
not included in pQTL analysis.
To test if additional pQTLs could be discovered by analyzing
all variants identified from whole-genome sequencing, per-
chromosome VCF files were converted to PLINK binary format
followed by association analysis using PLINK 2.0 (33). In total
52,783,013 autosomal variants were analyzed for association with
sortilin level, with a genome-wide significance threshold of P <
5 × 10−8. In addition to the single point analysis, a burden test
of rare variants was conducted using the MUMMY pipeline (41),
which builds on SMMAT, which performs a burden test, SKAT,
SKAT-O, and a hybrid test combining burden testing and SKAT
(42). In short, a GRM was calculated using GCTA (43), VCF
files were converted to GDS files, and a list of all variant sites
was created and filtered to include only variants with an allele
frequency <0.05. Subsequently, two different strategies were
applied. The first approach kept only severe variants (Ensembl
most severe consequence stronger than missense) and grouped
them by gene. The second approach included only coding
variants weighted by CADD score.
TABLE 1 | Cohort description (n = 1,173).
Patient characteristics (n = 1,173)
Sex, male 572 (48.8%)
Age (years) 57.2 ± 8.7
Body mass index (kg/m2) 26.8 ± 4.3
Cardiac Symptoms










Pack-year 11.7 ± 16.2
Diabetes mellitus
Type 1 7 (0.6%)
Type 2 62 (5.3%)
Cholesterol-lowering treatment 270 (23.3%)
Hypertensive treatment 410 (35.2%)
Biochemistry
Cholesterol (total, mmol/L) 5.5 ± 1.1
Glucose (fasting, mmol/L) 6.0 ± 1.2
Creatinine (mmol/L) 75.4 ± 14.2
eGFR (mL/min) 79.3 ± 10.4
Imaging




CAD severity group from coronary CTA
No CAD 546 (46.8%)
Mild CAD 251 (21.5%)
Moderate CAD 90 (7.7%)
Severe CAD 279 (23.9%)
Invasive coronary angiography
Obstructive CAD 117 (10.0%)
Association of Patient Characteristics With
Sortilin Levels
To establish the effect of a wide range of patient characteristics on
circulating plasma sortilin level, a multiple linear regression on
sortilin levels was performed, including patient characteristics,
cardiac symptoms, risk factors, biochemistry measurements, and
results from coronary CTA (Table 1).
Effect of Sortilin on Risk Stratification
PTP for CAD was calculated as previously described (44,
45) based on clinical risk factors including sex, age, angina
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FIGURE 1 | (A) Adjusted sortilin level from ELISA as function of adjusted sortilin level from OLINK. Pearson correlation coefficient (ρ) with significance level is noted
above the plot. (B) Comparison of sortilin level measured with ELISA on paired heparin and EDTA plasma samples.
symptoms, and number of risk factors (i.e., family history of early
CAD, smoking, dyslipidemia, hypertension, and/or diabetes).
The prediction accuracy for CAD severity groupings and
obstructive CAD was determined using PTP as baseline, which
then was compared to models that included circulating plasma
sortilin levels quantified by either OLINK or ELISA. The accuracy
of prediction was assessed using fivefold cross-validation, in
which the entire data first were divided in five folds. For CAD
severity groups, we used a linear model for approximation,
and for obstructive CAD, a logistic regression was applied. For
both disease end points, the general model was y=Xb+e, where
the response variable was either CAD severity group or the
binary disease outcome, X was the design matrix, and b was
the vector of parameter estimates (i.e., coefficients of intercept,
PTP, and sortilin by OLINK or ELISA), and e was the remaining
residual. For each combination of four folds, the parameters were
estimated (t) and used to predict the outcome of the individuals





′yt . The prediction accuracy of CAD severity
group was determined using Pearson correlation coefficient
between predicted value and observed CAD severity groups, and
the accuracy of discriminating CAD cases was determined by the
area under the receiver operating characteristic curve (AUC) as
implemented in the qgg package (37).
RESULTS
Patient Cohort
The cohort comprised 1,173 individuals in the age range 40
to 80 years, all referred to a CT scan for investigation for
CAD, primarily due to chest pain. Of the 1,173 patients, 117
patients (10%) were diagnosed with obstructive CAD at ICA,
with an equal distribution of disease cases across age classes
(Supplementary Figure 4A). Overall, 6% of females and 15%
of males in the cohort were diagnosed with obstructive CAD
(Supplementary Figure 4B). Those diagnosed with obstructive
CAD were on average older than those not diagnosed with CAD
(Supplementary Figure 4C). The baseline characteristics of the
cohort can be found in Table 1.
Circulating Sortilin Levels
In a high-sensitivity ELISA assay, the mean sortilin plasma
level was 30.99 ng/mL [95% confidence interval (CI) = 30.21–
31.76 ng/mL] prior to adjustment and normalization. As OLINK
only provides relative protein levels, the actual sortilin plasma
levels between assays cannot be readily compared. However,
when comparing the actual levels quantified by ELISA with the
relative levels by OLINK, a rather poor correlation coefficient of
ρ = 0.21 (P ≪ 0.001) was observed (Figure 1A). To explore
if the anticoagulant used could explain part of the difference
between the assays, we performed ELISA on paired heparin and
EDTA plasma samples from 44 randomly selected Dan-NICAD
individuals. While we find variation in the absolute level of
sortilin between heparin and EDTA plasma for single individuals,
we find on average no systematic difference between EDTA and
heparin plasma. The correlation coefficient was ρ = 0.75, and
slope= 0.97, indicating no systematic difference (Figure 1B).
Genetic Analysis of Circulating Sortilin
To investigate howmuch of the variation observed in sortilin was
explained by genetic variation, the SNP heritability (ĥ2SNP) was
estimated. None of the observed variation could be attributed
to genetic variation as the estimates for sortilin measured with
OLINK and ELISA were ĥ2SNP = 1.4× 10–9 (SE= 0.23) and ĥ
2
SNP
= 9.4× 10–10 (SE= 0.23), respectively.
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FIGURE 2 | Protein quantitative trait loci for variation in sortilin level quantified with OLINK (top panel) and ELISA (bottom panel). The x-axis is chromosomal position,
and the y-axes show the negative logarithm base-10 to the P-values from regression of circulating sortilin level on 4,658,994 autosomal genetic variants. The
horizontal lines indicate the genome-wide significant threshold of 5 × 10−8, and points highlighted in purple are genetic variants surpassing this threshold. The two
violin plots show the association between adjusted sortilin level and genotypes for the two identified cis-pQTLs.
Whole-genome regressions were performed to identify
genetic variants associated with variation in sortilin levels.
One pQTL for circulating sortilin measured with OLINK was
identified on chromosome 1p13.3 with index SNP rs11590351 (P
= 2.1 × 10−11) (Figure 2), and another pQTL using the ELISA
data was identified also on chromosome 1p13.3 with the index
SNP rs602633 (P = 2.1 × 10−11) (Figure 2). Interestingly, the
two pQTLs are located on either side of SORT1 and is not within
the same LD block (Figure 3). The OLINK pQTL is positioned
upstream of SORT1, with the minor allele (C, MAF= 0.25) being
associated with decreased sortilin, whereas the ELISA pQTL is
located downstream of SORT1 where the minor allele (T, MAF
= 0.25) is associated with increased sortilin (Figures 2, 3). The
index variant for ELISA, rs602633, is also the index variant for
CAD, with the major allele, G, being the risk variant (16).
Rare variant analysis identified 23,833 variants with more
severe consequences thanmissense across 7,003 genes (median of
two variants per gene) (Supplementary Figure 5). Limiting the
analysis to coding variants weighted by CADD score identified
1,052,840 variants across 17,913 genes (median of 48 variants
per gene). Neither of the two rare variants analyses found any
significant associations between variants and circulating sortilin
levels (Supplementary Figure 6). Analysis of all WGS variants
individually did not provide any additional information on
the molecular genetic basis of variation in circulating sortilin
(Figure 3).
Effect of Patient Characteristics on Sortilin
Levels
A multiple linear regression, testing for the effect of a number
of patient characteristics, showed no significant effect of any of
the tested variables (Figure 4). Importantly, no correlation was
seen between sortilin levels and CACS (CACS group) or disease
severity (CAD severity group) for either of the methods.
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FIGURE 3 | Regional plot of pQTLs identified for sortilin measured with OLINK and ELISA for common variants (MAF >0.05) and for all segregating variants identified
by whole-genome sequencing (WGS).
Sortilin and Risk Stratification
To test if sortilin could provide an improvement in risk
stratification of patients in addition to the traditional risk factors,
we calculated the PTP for obstructive CAD with and without
sortilin. The PTP calculated from traditional risk factors had,
as expected, modest predictive power in stratifying patients in
the four groups of increasing CAD severity (Pearson correlation
ρ = 0.39, Figure 5). Including plasma sortilin levels from
either OLINK or ELISA did not improve the predictive accuracy
(Figure 5). The PTP had a mean accuracy for discriminating
obstructive CAD evaluated with AUC of 0.72 (95% CI = 0.66–
76) (Figure 6), which was marginally lower when including
circulating sortilin (Figure 6).
In summary, we have found two independent cis-pQTLs
for soluble sortilin, where the pQTL downstream of SORT1 is
colocalized with the CAD risk locus. However, we found no
correlation between sortilin and CAD severity or coronary artery
calcification, and no improvement in risk stratification for CAD,
when adding sortilin on top of clinical risk factors, in patients
suspected of CAD.
DISCUSSION
In this study, we investigated in a large well-described low- to
intermediate-risk chest-pain cohort whether variation in plasma
levels of soluble sortilin was under genetic influence and explored
the added value of including soluble sortilin in risk stratification
of patients with suspected CAD.
We identified two independent cis-pQTLs on chromosome
1p13.3 for circulating plasma sortilin measured with ELISA and
OLINK (Figures 2, 3). For the pQTL downstream of SORT1,
the lead SNP was rs602633; we found that the major G allele
was associated with lower sortilin in plasma, which is in line
with the well-known directional effect observed in the human
liver (12), where the major G allele is associated with lower
SORT1 transcript levels. As the major G allele of rs602633 in
large GWASs is strongly associated with higher LDL cholesterol
(16, 46), one would expect lower sortilin levels in the plasma in
individuals with CAD.
The few published studies investigating sortilin levels in
smaller CAD study populations find either a positive or negative
correlation (24, 26). In a cross-sectional study with 31 CAD
patients and 116 healthy controls, Oh et al. (26) found higher
levels of plasma sortilin in patients with CAD. In contrast, a
study by Ogawa et al. (24) with 91 CAD patients and 189 healthy
controls found lower plasma sortilin in CAD patients. Both
studies used ELISA to detect sortilin. In the Dan-NICAD cohort,
we were not able to detect any significant association between
circulating sortilin and CAD.
We found a relatively low correlation between sortilin levels
measured using two different methods applied. The reason for
this can be assay or sample dependent. To our knowledge, there
have not been any published studies comparing measurement of
sortilin in ELISA (gold standard) and OLINK or other discovery
platforms head-to-head. Differences between ELISA of specific
analytes and various omics platforms, such as SOMAscan,
Luminex xMAP, Myriad RBM, and OLINK, have been widely
observed (47). Raffield et al. compared 20 different proteins
measured using the Luminex xMAP and the SOMAscan platform
and found that the correlations range from−0.13 to 0.97 between
proteins, and nearly half had a correlation coefficient of <0.5.
Furthermore, Raffield et al. compared pQTL analyses on the
same cohort (SPIROMICS and COPDGene) measuring the same
proteins but with different methods (Myriad RBM or OLINK
and SOMAscan) (47) and found this affected the ability to
detect cis-pQTLs. Additionally, there was very low correlation
between proteins measured with the various methods in 20–40%
of cases. It is clear that many of the high-throughput discovery
methods such as OLINK, Myriad RBM, and SOMAscan need
further validation by more conventional methods with true
quantification, such as ELISA. In the OLINK assay, heparin
plasma was used, whereas in the high-sensitivity ELISA assay,
Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 April 2021 | Volume 8 | Article 652584
Møller et al. Sortilin as a Biomarker
FIGURE 4 | Regression coefficients (β estimates) from multiple linear regression of circulating sortilin (adjusted values) measured with OLINK and ELISA technologies.
Error bars indicate the standard error on the estimate. Filled symbols indicate that the β estimates are significantly different from zero.
EDTA plasma was used. Thrombocytes contain sortilin (24), and
neither heparin nor EDTA completely inhibited degranulation
of thrombocytes (48). The degranulation is most pronounced in
serum (24). Therefore, the anticoagulant may have affected the
levels of sortilin in plasma. We did, however, not find on average
any systematic difference between EDTA and heparin plasma
when measuring paired EDTA and heparin samples with ELISA
(Figure 1B).
Although both assays measure plasma sortilin, the detection
is by different means. OLINK relies on the PEA technology,
which uses a matched pair of monoclonal antibodies, each tagged
with a unique DNA sequence. When the two antibodies bind
sortilin, the DNA tags get into proximity and can hybridize,
and a quantitative polymerase chain reaction can be performed.
The output of OLINK is therefore relative NPX values on a
log2 scale. In contrast, the ELISA method relies on coating of
plates with polyclonal antibody, recognizing several isoforms
in sortilin. Detection is with a monoclonal antibody and a
secondary horseradish peroxidase–coupled antibody. Each plate
includes a standard curve with samples of known sortilin
concentration, allowing for absolute quantification of sortilin
levels. As both techniques are based on antibody detection, one
can speculate that posttranslational modifications of sortilin,
such as glycosylation or carbamoylation, may have an impact
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FIGURE 5 | Prediction of CAD severity (0: no CAD, 1: mild CAD, 2: moderate CAD, 3: severe CAD) using (A) pretest probability (PTP) without and with sortilin
measurements by (B) OLINK and (C) ELISA. The overall correlation (ρ) between predicted value and CAD severity group across the five validation sets is indicated
above each plot.
on the detection efficacy, as this can mask epitopes, and may
impact the assays differently. To determine if posttranslational
modifications are responsible for the low correlation between
the two assays, it will require further analyses including Western
blotting and mass spectometry, which is beyond the scope of
this study.
The variation found in sortilin levels in human plasma was
not explained by traditional risk factors for CAD. Furthermore,
the GWAS of plasma sortilin levels identified two independent
cis-pQTLs (one for each of the platform used) at 1p13.3, where
SORT1 resides. The rare variant analyses did not detect any
additional pQTLs. The source of sortilin in plasma may be a
result of shedding from various tissues as sortilin is ubiquitously
expressed (19, 22, 49–51). Sortilin may also be present in plasma
as extracellular vesicles secreted by smooth muscle cells (23)
or can be released from degranulated thrombocytes (24). The
main source of variation is currently unknown, and the genetic
contribution is low.
The lead pQTL SNPs for OLINK and ELISA sortilin were
located upstream and downstream of SORT1, respectively. As
the two loci were genetically uncoupled, this could indicate
the existence of at least two regulatory sequences upstream
and downstream of the SORT1 gene. Two large pQTL studies
on OLINK proteins have been published (52, 53). One study
investigated 1,992 individuals on OLINK CVD II panel (includes
sortilin) on EDTA plasma. Recently, a second large pQTL study
was published comprising 1,328 individuals on the CVD II panel
on serum samples. Bretherick et al. (53), were able to detect a cis-
pQTL for sortilin in plasma at rs7528419, which is in strong LD
with our lead SNP. Gilly et al. (52), however, were not able to
detect any pQTL for serum sortilin. It is well-known that sortilin
(among other proteins) can be released from degranulating
thrombocytes, especially in serum (24). This is likely why a pQTL
is not detected by Gilly et al. (52). Further evidence for the cis-
pQTL downstream of SORT1 for plasma sortilin, i.e., rs646776
and rs12740374, was found in other studies based on Luminex
platform (54) and SOMAscan (55). None of the studies validated
the findings using more than one platform.
As elevated total cholesterol and diabetes often are highly
correlated, it was not surprising that we observed a tendency
of non-zero regression estimates for both total cholesterol level
and diabetes status. That diabetes status and elevated cholesterol
showed a tendency of being associated with increased sortilin
level in plasma is in agreement with sortilin being involved in
glucose homeostasis (56, 57) and that diabetes subjects have
previously been shown to have elevated sortilin levels (28).
However, this positive correlation was not identified with ELISA.
Diabetes does involve random glycosylation of proteins, and it is
possible that this influences the detection efficacy in the above
assays. Although obesity is a major risk factor of CAD, and
sortilin is highly expressed in adipocytes (58), plasma sortilin
levels weakly and negatively correlate (OLINK) with body mass
index in our current study. No correlation was detected in ELISA.
Additionally, even though plasma sortilin and liver sortilin seem
to be regulated in the same direction by the major allele, this is
not true for fat tissue (12). As there are many possible sources
of sortilin in plasma, it does seem that fat is not a major source
of sortilin.
The ability to accurately stratify patients with symptoms of
CAD is challenging, and most stratification models rely on
classical risk factors, such as age, sex, and symptoms (59), and
degree of artery calcification (45). With the recent developments
in omic’s technologies, much effort has been put into combining
traditional risk factors with omic’s derived risk scores, which
has so far shown some increased accuracy in discriminating
healthy from affected patients (60–62). We used the PTP with
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FIGURE 6 | Prediction accuracies measured by area under the receiver operating characteristic curve (AUC) for discrimination of obstructive CAD. White dots indicate
median AUC across the five validation sets, and the mean AUC (x) for each model is indicated above each violin. Predictions were based on the pretest probability
(PTP) with and without sortilin measurements by OLINK and ELISA.
and without sortilin measurements to investigate whether adding
sortilin improved the accuracy of risk stratification. We did not
find any improvement in risk prediction by including sortilin
combined with the traditional risk factors (Figures 5, 6). This
is in line with Bom et al. (63), who in a cohort of 203 patients
with suspected CAD utilized machine learning to identify two
protein signatures predicting high-risk plaques and absence of
CAD, respectively. Neither protein signature included sortilin.
In conclusion, we have identified two cis-pQTLs for plasma
sortilin at 1p13.3, where one of the pQTLs is a strong risk
variant for CAD, with the risk allele for CAD driving lower
levels of soluble sortilin in plasma, which is the same direction
as the SORT1 transcript in the human liver. We find no
association of plasma sortilin with CAD severity or coronary
artery calcification, and sortilin did not improve existing risk
classification in a clinical setting. Overall, in a well-characterized
cohort of patients, sortilin was not a useful biomarker for CAD.
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